Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial. (April 2021) - Martin, M.; Holmes, F.A.; Moy, B.; Mansi, J.; Gnant, M.; Buyse, M.; Barrios, C.; Bryce, R.; Wong, A.; Chan, A.